How USDM Enables Clinical Trial Data Exchange Across EDC, CTMS, and Other Systems

Regulatory and vendor-conformance details in this article were verified as of September 23, 2026. USDM version numbers, ICH M11 status, and vendor listings change as the standard matures, so a reader consulting this piece later should confirm current status against the primary sources cited below.

Introduction

A protocol gets approved on a Tuesday. By Friday, three different teams are retyping the same eligibility criteria, the same visit schedule, and the same endpoint definitions into three different systems: the EDC build, the CTMS milestone tracker, and the randomization and trial supply platform. In fragmented trial stacks, those systems often do not share a common study definition, so the retyping happens by hand, and errors creep in every time. TransCelerate BioPharma states that an average lag of four months separates protocol approval from study startup, and it names document-based duplication of effort as one contributor to that lag, though the organization does not publish a methodology breaking out how much of the four months traces specifically to manual system handoffs versus other causes ^[2].

The Unified Study Definitions Model, known as USDM, is the CDISC and TransCelerate standard built to address exactly this kind of duplication. It is not a new piece of software. USDM enables clinical trial data exchange by giving EDC, CTMS, and protocol authoring systems a shared way to represent the same study design facts: a logical data model that defines standardized classes and attributes, a controlled terminology binding so conformant systems can interpret defined terms consistently, a REST API specification for moving that data between systems, and conformance rules that let an implementation be checked against the model ^[1]. This article looks at what USDM actually is, how a protocol's data moves from an authoring tool through to EDC and CTMS in practice, and where the standard still has real limits.

Why This Topic Matters in Clinical Trials

Clinical trials run on the same handful of facts repeated across a dozen systems: inclusion and exclusion criteria, the schedule of activities, arms and interventions, objectives and endpoints, and the visit windows that structure everything else. Historically, each of those facts lived first in a Word document, then got manually transcribed into an EDC build specification, a CTMS study plan, a randomization system configuration, and a clinical trial registry entry. Every transcription step is a chance to introduce a discrepancy between the protocol and the system meant to operationalize it.

The Digital Data Flow initiative, a joint CDISC and TransCelerate effort, was created specifically to address this. Its stated aim is to "improve clinical study design and to accelerate clinical trial start-up through automation of processes" by moving the industry from a document-centric model to a data-centric one ^[2]. USDM is the data model at the center of that effort. Rather than each vendor inventing its own internal representation of a protocol, USDM defines standardized classes and attributes for study entities such as populations, interventions, activities, and encounters, so that any conformant system can produce, consume, or exchange that structured information without a human retyping it first ^[1].

Kenneth Getz and colleagues at the Tufts Center for the Study of Drug Development have separately quantified two distinct costs that give this problem its financial weight, though the two figures measure different things and should not be added or multiplied together. Direct trial conduct costs, the operating expense of running a trial once it is underway, run to $55,716 per day for Phase III studies and $23,737 per day for Phase II studies, with a combined mean across Phase II and III of roughly $40,000 per day ^[5]. Separately, a single day of delay in getting an approved drug to market carries an average cost of approximately $800,000 in unrealized sales as of the researchers' 2023 analysis, a figure they note has fallen sharply from older 1990s estimates ^[5]. Neither figure is a validated cost-per-day specifically for study startup delay, and Tufts does not calculate what a four-month startup lag costs in aggregate. What the two figures establish is a more general point: every day a study is not enrolling or a product is not on the market has a real, published cost, which is the backdrop against which sponsors and CROs have funded a multi-year standardization effort rather than leaving system fragmentation to individual vendors to solve.

Current Evidence and Research Landscape

USDM has moved through several public versions since its first release, each expanding what the model can represent. Version 1.0 shipped in August 2022 and established the reference architecture. Version 2.0 followed in June 2023, adding biomedical concepts and protocol template support. Version 3.0, released in April 2024, extended alignment with ICH M11 and added support for more complex study designs. Version 4.0, published in June 2025, is the current release ^[1]. CDISC published textual conformance rule specifications for version 3.0 in December 2024 and for version 4.0 in June 2025, then released executable versions of those rules through the CDISC library in December 2025, giving implementers a way to check a study definition against the model programmatically rather than by manual review alone ^[14]. The Digital Data Flow roadmap documents four completed development phases, moving from an initial reference architecture built between July 2021 and July 2022 through conformance specification work that continued into May 2025, plus a planned fifth phase. CDISC's page gives conflicting signals on what comes next: it lists an anticipated Phase 5 timeline of May 2025 to April 2026 in one place, while a separate note on the same page still describes Phase 5's scope as being developed. The current status of Phase 5 is unclear from CDISC's public materials as of this writing ^[1].

The vendor landscape has not waited for a finished, universally adopted standard before building against USDM, and engagement is concentrated among vendors actively participating in the DDF initiative. Two systems reporting the same USDM version number is a starting point for interoperability, not a guarantee that their implementations exchange data without additional mapping work, which is why confirming current conformance directly with a vendor remains worthwhile before relying on the listing alone.

Operational Impact for Sponsors, CROs, and Sites

How the Data Actually Moves Between Systems

USDM itself defines what a study looks like as data. It does not, on its own, move that data into any particular EDC or CTMS screen. No single published source specifies one mandatory sequence for every implementation, but based on how USDM's components are documented, a representative implementation pattern looks like this:

1. A protocol authoring tool captures the study design (eligibility criteria, schedule of activities, arms, objectives, and endpoints) and outputs it as a structured USDM study definition, commonly represented as JSON, though USDM does not require JSON specifically, conforming to a specific USDM version ^[1].
2. That output can be checked against CDISC's published conformance rules, which validate whether the structure and terminology match what the model requires ^[1]. Passing those checks confirms structural and terminology conformance; it does not by itself confirm that the represented eligibility criteria, endpoints, or schedule are clinically correct, which is a separate review question addressed in step 4.
3. A downstream system, an EDC study build tool or a CTMS, commonly needs an adapter or mapping layer that translates the generic USDM classes into that system's own configuration objects, unless that system natively consumes the USDM representation directly. USDM's data model and a given vendor's internal schema are not guaranteed to be identical even when both target the same USDM version ^{[1] [4]}.
4. Study build and data management staff still review the result, particularly at points like eligibility criteria and endpoint definitions where a mapping error is easy to introduce and costly to miss.
5. When the protocol is amended, the change has to be re-authored in the USDM representation, re-validated, and re-propagated through the same chain, which is why amendment version control at the data layer is one of the standard's harder open problems ^[4].

Treat this as an illustration of where the engineering work sits, not a certified or universal workflow: individual vendors implement it differently, and some steps may be combined, automated, or handled manually depending on the tool. Every step in that chain is a place where USDM's promise depends on vendor implementation quality, not on the standard alone. The pieces that USDM defines, the model, the terminology, the API, and the conformance rules, are the connective tissue. Based on how those components are documented, a significant share of the implementation effort may sit in the mapping and validation work described in steps 3 and 4, though no published source quantifies this split across real implementations ^{[1] [4]}.

With that sequence in mind, the mechanical promise of USDM is real but conditional. Once a protocol's design elements exist as structured USDM data rather than narrative text, an EDC vendor's study build tool can, in principle, use that data to inform form specifications and visit structures instead of a data manager manually translating a 120-page PDF into a build specification. A CTMS drawing its visit schedule from that same structured source, rather than from a separately maintained project plan, is a plausible extension of the same idea; it is this article's own illustration of where the model could apply, not a capability documented in the sources cited here. Whether a specific system today auto-populates configuration end to end, versus using the USDM data as a structured reference during manual build, varies by vendor and is not something the published DDF directory confirms on its own ^[7]. Medidata's own analysis of digital protocols frames the broader shift as moving away from legacy workflows that create "operational inefficiencies and transcription errors" toward structured components that can be reused across trials and pushed to downstream systems through an API rather than re-keyed each time ^[8].

For sponsors and CROs running large portfolios, the more durable value may sit in reusability rather than any single study build. A standardized eligibility criterion, endpoint definition, or schedule of activities element, once encoded in USDM, becomes a component that a second trial can pull in rather than redraft from scratch. That is a different kind of efficiency than a faster EDC build: it compounds across a program rather than resetting with every new protocol.

None of this removes the operational burden entirely, and the industry's own vendor commentary is candid about where the model still runs into friction. An analysis published by CRScube identifies what it terms a timeline paradox: USDM-driven automation works best against a finalized protocol, but current practice often allows partial EDC and CTMS configuration to begin from an earlier protocol synopsis, before every design element is locked ^[4]. Requiring full USDM conformance before system setup can begin could, in some workflows, slow initial configuration rather than speed it, at least during the transition period while teams still maintain parallel document-based and data-based processes ^[4].

Protocol amendments raise a related concern. A structured, machine-readable protocol makes it easier to propagate a change consistently across every downstream system, which is the point of the standard. But it also means an amendment now needs disciplined version control and change management at the data layer, not just a redlined document routed for signatures, and the CRScube analysis flags this as a real implementation risk rather than a solved problem ^[4].

Regulatory and Documentation Considerations

The regulatory driver behind USDM adoption is ICH M11, the harmonized guideline establishing a clinical electronic structured protocol template and its accompanying technical specification. The ICH Assembly adopted M11 at Step 4, the point in the ICH process where regulatory members agree a guideline has reached sufficient international consensus ^[12], on November 19, 2025, at its meeting in Singapore ^[13]. From Step 4 the guideline moves directly into Step 5, regional implementation, where each ICH region applies it through its own regulatory procedures ^[12]. The European Medicines Agency published its Step 5 guideline, template, and technical specification on December 15, 2025 ^[10]. The U.S. Food and Drug Administration issued final M11 guidance in May 2026 as part of its regional Step 5 implementation, describing that guidance as finalizing the draft versions it circulated for comment in December 2022 and June 2025 ^[9]. Published Step 5 materials mean the regulatory text is final in each region; whether a given sponsor's own systems and processes are fully aligned with it is a separate, ongoing question this article does not attempt to answer. Sponsors working against M11 today are implementing a guideline that has cleared both international consensus and regional finalization in two of its largest markets, rather than a draft under consultation.

The relationship between M11 and USDM is architectural, and it is worth being precise about its scope. According to a CDISC presentation on the topic, USDM "accommodates the M11 elements and their semantics" and provides an M11-specific view within the broader model ^[6]. That presentation is also explicit that the M11 template itself can be exchanged using several formats, including a human-readable electronic document, a machine-readable form, FHIR profiles, and a stylesheet, and that technical implementation guides may be needed for different use cases ^[6]. USDM and its FHIR-based transport model are a supported, industry-backed path for implementing M11 in a structured, exchangeable form, not the only format M11 permits. The layered relationship runs through a conceptual model that standardizes how protocol information is stored independent of format, a USDM view that maps M11 elements into structured classes with controlled terminology, and a FHIR-based transport model for technical exchange between systems that choose to implement it ^[6].

This matters for documentation teams because it changes what "the protocol" can be as a regulatory artifact, without changing what it must be. M11 and USDM together make it possible to maintain a structured, machine-readable representation of a protocol alongside the human-readable document, and downstream systems built to read that structured layer, including EDC, CTMS, and SDTM-generating tools, can inherit whatever consistency it carries ^[1]. Neither ICH nor the cited CDISC materials establish that the structured representation supersedes the approved, human-readable protocol as the controlling regulatory document. The approved protocol remains the artifact regulators and ethics committees act on; the structured USDM version is the computable companion to it.

AI and Automation Perspective

One open-source reference implementation is worth a caveat before discussing automation. The CDISC-hosted usdm Python package on GitHub, which converts Excel-based study definitions into USDM-formatted JSON, notes explicitly that it "was, originally, not intended for public use and, consequently, only informal testing has been performed on the package to date" ^[3]. That statement describes the maturity of one specific tool, not the USDM standard itself, which has gone through multiple public review cycles, versioned releases, and, as of December 2025, executable conformance rules ^{[1] [14]}. Even so, it is a reasonable prompt for caution: automated pipelines built on any USDM tooling, reference implementation or commercial, still need human review at the points where structured data gets generated from a protocol and where it gets consumed by a downstream system.

Several vendors in the DDF directory describe positioning AI at the protocol authoring step, self-reporting that they extract structured study data from draft protocol text as part of their workflow; the directory does not independently verify these descriptions or confirm that the resulting output actually conforms to USDM ^[7]. If that extraction task works as vendors describe it, it is at least a plausible fit for automation in principle: mapping unstructured protocol language to a fixed set of USDM classes and controlled terms is a bounded, schema-constrained task, a different kind of problem from open-ended summarization or drafting. Whether any specific vendor's implementation delivers that reliably is not something this article verifies, and doing so would not remove the need for a human reviewer to confirm that any extracted structure matches clinical and regulatory intent, particularly around eligibility criteria and endpoint definitions where a subtle misclassification can propagate into every downstream system that consumes it.

The CRScube analysis raises a separate limitation worth carrying into any automation plan: a clinical protocol does not cover every operational detail a trial needs. Inventory management for randomization and trial supply systems is one example the analysis calls out specifically as falling outside protocol scope, meaning USDM-driven automation has a real boundary, and systems downstream of that boundary still require separate configuration ^[4].

How Kitsa Fits Into This Problem

Kitsa's KScribe platform generates protocols, informed consent forms, investigator brochures, and related regulatory documents as part of an AI-native authoring workflow ^[11], which places it upstream of the USDM data flow described in this article by design intent rather than by a claimed USDM export or conformance status. A protocol authored with structure and controlled terminology in mind from the outset is, in principle, easier to map into a USDM representation than one drafted as free text and structured after the fact. Realizing that benefit for a specific study still depends on the same validation and mapping work described above, and readers evaluating any authoring tool for USDM readiness, including KScribe, should confirm the specific USDM version supported and how conformance is validated before relying on it for downstream automation.

Key Takeaways

• USDM is a CDISC and TransCelerate data model, controlled terminology binding, API specification, and set of conformance rules, not a standalone software product, built to let protocol data move between systems without manual retyping ^[1].
• TransCelerate reports an average four-month lag between protocol approval and study startup and names document-based duplication as one contributor, though it does not publish a breakdown of how much of that lag traces specifically to manual system handoffs ^[2].
• USDM has released four major versions since August 2022, with version 4.0 published in June 2025; CDISC's page gives conflicting signals on the DDF project's fifth phase, listing an anticipated May 2025 to April 2026 timeline in one place while elsewhere still describing the phase's scope as being developed ^[1].
• TransCelerate's DDF Solution Directory shows vendors across protocol authoring, EDC, and CTMS-adjacent categories, including Merative Zelta, PHARMASEAL, and Nurocor, self-reporting USDM version compatibility; TransCelerate explicitly disclaims the accuracy of these listings and does not verify or endorse them, and the listing's own category labels are not always internally consistent ^[7].
• ICH M11 was adopted at Step 4 by the ICH Assembly on November 19, 2025 ^[13], then moved into Step 5 regional implementation: the EMA published its Step 5 materials on December 15, 2025, and the FDA finalized its own M11 guidance in May 2026. USDM is one supported implementation path for M11, not the only format the guideline permits ^{[6] [9] [10]}.
• Known adoption barriers include a timeline paradox around when in the protocol lifecycle automation can realistically begin, added complexity in amendment version control, the mapping work needed between USDM's generic model and any given system's internal schema, and the fact that protocols do not cover every operational system a trial depends on ^{[1] [4]}.
• Direct trial conduct costs of roughly $40,000 per day for combined Phase II and III studies, and an estimated $800,000 per day in unrealized sales for a delayed marketed product, are two separate published figures that illustrate why delay is costly, though neither is a validated per-day cost of startup delay specifically ^[5].

FAQ

References

1. [1]CDISC. "Digital Data Flow (DDF) for Clinical Trial Protocols." CDISC. Accessed September 23, 2026. https://www.cdisc.org/ddf
2. [2]TransCelerate BioPharma. "Digital Data Flow." TransCelerate BioPharma Inc. Accessed September 23, 2026. https://www.transceleratebiopharmainc.com/initiatives/digital-data-flow/
3. [3]CDISC. "cdisc-org/usdm." GitHub repository. Accessed September 23, 2026. https://github.com/cdisc-org/usdm
4. [4]CRScube. "The Promise and Challenges of the Unified Study Definition Model (USDM)." CRScube, 2025. Accessed September 23, 2026. https://www.crscube.io/resource/the-promise-and-challenges-of-the-unified-study-definition-model-%28usdm%29
5. [5]Smith, Z., DiMasi, J., Getz, K. "Quantifying the Value of a Day of Delay in Drug Development." Tufts Center for the Study of Drug Development, August 2024. Accessed September 23, 2026. https://csdd.tufts.edu/sites/default/files/2025-02/Aug2024%20Day%20of%20Delay%20White%20Paper%20Final.pdf
6. [6]Halsey, N. "ICH M11: Clinical electronic Structured Harmonised Protocols." CDISC Europe Interchange, 2025. Accessed September 23, 2026. https://www.cdisc.org/sites/default/files/2025-05/ICH%20M11%20Protocols%20-%20CDISC%20Europe%202025%20-%20Nick%20Halsey.pdf
7. [7]TransCelerate BioPharma. "Digital Data Flow (DDF) Solution Directory." Self-reported vendor listing; accuracy not independently verified by TransCelerate. Accessed September 23, 2026. https://transcelerate.github.io/ddf-directory/directory/directory.html
8. [8]Medidata. "The Digital Protocol: What It Is & Why It's the Future of Clinical Trials." Medidata Blog, April 15, 2026. Accessed September 23, 2026. https://www.medidata.com/en/life-science-resources/medidata-blog/digital-protocol/
9. [9]U.S. Food and Drug Administration. "M11 Clinical Electronic Structured Harmonised Protocol (CeSHarP); International Council for Harmonisation; Guidance for Industry; Availability." Federal Register, May 22, 2026, Document No. 2026-10295. Final guidance finalizing the draft guidances circulated for comment on December 22, 2022, and June 6, 2025. Docket No. FDA-2022-D-3054. Accessed September 23, 2026. https://www.federalregister.gov/documents/2026/05/22/2026-10295/m11-clinical-electronic-structured-harmonised-protocol-cesharp-international-council-for
10. [10]European Medicines Agency. "ICH M11 Guideline on Clinical Electronic Structured Harmonised Protocol (CeSHarP), Template, and Technical Specification." Step 5 regional implementation, published December 15, 2025. Reference EMA/CHMP/ICH/778799/2022. Accessed September 23, 2026. https://www.ema.europa.eu/en/ich-m11-guideline-clinical-study-protocol-template-technical-specifications-scientific-guideline
11. [11]Kitsa. "KScribe: AI-Powered Regulatory and Clinical Document Generation." Kitsa.ai. Accessed September 23, 2026. https://kitsa.ai/regulatory-document-generation
12. [12]International Council for Harmonisation (ICH). "Formal ICH Procedure." Accessed September 23, 2026. https://admin.ich.org/page/formal-ich-procedure
13. [13]International Council for Harmonisation (ICH). "M11 Harmonised Guideline: Clinical Electronic Structured Harmonised Protocol (CeSHarP)." Adopted by the Regulatory Members of the ICH Assembly under Step 4, November 19, 2025. Accessed September 23, 2026. https://database.ich.org/sites/default/files/ICH_Step4_M11_Final_Guideline_2025_1119.pdf
14. [14]CDISC. "USDM v3.0 and v4.0 Errata." Textual rule specifications published December 18, 2024 (v3.0) and June 3, 2025 (v4.0); executable versions published December 2025. Accessed September 23, 2026. https://www.cdisc.org/ddf/usdm-errata-3-4